Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson’s disease
2024 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson’s disease
Tatenhorst, L.; Maass, F.; Paul, H.; Dambeck, V.; Bähr, M.; Dono, R. & Lingor, P. (2024)
Scientific Reports, 14(1). DOI: https://doi.org/10.1038/s41598-024-54800-8
Documents & Media
Details
- Authors
- Tatenhorst, Lars; Maass, Fabian; Paul, Hannah; Dambeck, Vivian; Bähr, Mathias; Dono, Rosanna; Lingor, Paul
- Abstract
- Abstract Glypicans are biomarkers for various pathologies, including cardiovascular disease, cancer and diabetes. Increasing evidence suggests that glypicans also play a role in the context of neurodegenerative disorders. Initially described as supporting functionality of synapses via glutamate receptors during CNS development, Glypican 4 (GPC-4) also plays a role in the context of dementia via tau hyperphosphorylation in Alzheimer’s disease, which is also a co-pathology in Parkinson’s disease dementia. However, clinical evidence of circulating GPC-4 in Parkinson’s disease (PD) is missing so far. We therefore investigated GPC-4 in biofluids of PD patients. We analyzed GPC-4 levels in cerebrospinal fluid (CSF, n = 140), serum (n = 80), and tear fluid samples (n = 70) of PD patients and control subjects in a similar age range by ELISA (serum, CSF) and western blot (tear fluid). Expression of circulating GPC-4 was confirmed in all three biofluids, with highest levels in serum. Interestingly, GPC-4 levels were age-dependent, and multiple regression analysis revealed a significant association between GPC-4 serum levels and MoCA score, suggesting an involvement of GPC-4 in PD-associated cognitive decline. Furthermore, stratification of PD patients for vascular risk factors revealed a significant increase of GPC-4 serum levels in PD patients with vascular risk factors. Our results suggest GPC-4 as a clinical biomarker for vascular risk stratification in order to identify PD patients with increased risk of developing dementia.
- Issue Date
- 2024
- Journal
- Scientific Reports
- eISSN
- 2045-2322
- Language
- English
- Sponsor
- Centers of Excellence in Neurodegeneration – Pathfinder III Awards
Herzzentrum Göttingen